The Filing Desk

C4 Therapeutics vs Editas Medicine

C4 Therapeutics CCCC · Editas Medicine EDIT · Biotechnology

Editas Medicine reported revenue of $40 million in fiscal 2025, about the same as C4 Therapeutics' $36 million in fiscal 2025. C4 Therapeutics' revenue grew 1.0% in its latest year, and Editas Medicine's grew 25.4%. C4 Therapeutics had an operating margin of -320.5%, against -394.9% at Editas Medicine. Free cash flow was −$99 million at C4 Therapeutics and −$166 million at Editas Medicine.

Side by side

C4 TherapeuticsEditas Medicine
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$36M$40M
Revenue growth1.0%25.4%
Revenue growth a year, last 5 years—−14.9%
Gross margin——
Operating margin−320.5%−394.9%
Net margin−292.1%−395.0%
Free cash flow−$99M−$166M
Free cash flow margin−276.2%−409.3%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count19.5%7.8%
Last close$2.44$1.71
P/E at the last close——
Insider trades, last 12 monthssold $22,200sold $106,705
Piotroski F-score3 of 82 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
C4 TherapeuticsEditas Medicine
Operating margin
Percent of revenue
C4 TherapeuticsEditas Medicine
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
C4 TherapeuticsEditas Medicine

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the C4 Therapeutics and Editas Medicine pages.